Navigation Links
Rosetta Genomics and Columbia University Medical Center to Develop MicroRNA-based Diagnostics for Leukemia and Non Hodgkin Lymphoma
Date:12/13/2007

tatement Disclaimer

Various statements in this release concerning Rosetta's future expectations, plans and prospects, including without limitation, statements relating to the role of microRNAs in human physiology and disease, including heart disease, and the potential of microRNAs in the diagnosis and treatment of disease constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward- looking statements as a result of various important factors, including risks related to: Rosetta's approach to discover and develop novel diagnostics and therapeutic products, which is unproven and may never lead to marketable products; Rosetta's ability to fund and the results of further pre-clinical and clinical trials; Rosetta's ability to obtain, maintain and protect the intellectual property utilized by Rosetta's products; Rosetta's ability to enforce its patents against infringers and to defend its patent portfolio against challenges from third parties; Rosetta's ability to obtain additional funding to support its business activities; Rosetta's dependence on third parties for development, manufacture, marketing, sales, and distribution of products; Rosetta's ability to successfully develop its product candidates, all of which are in early stages of development; Rosetta's ability to obtain regulatory approval for products; competition from others using technology similar to Rosetta's and others developing products for similar uses; Rosetta's dependence on collaborators; and Rosetta's short operating history; as well as those risks more fully discussed in the "Risk Factors" section of Rosetta's Annual Report on Form 20-F for the year ended December 31, 2006 as filed with the Securities and Exchange Commission. In addition, any forward- looking statements represent Rosetta's views only as of the date of this release and s
'/>"/>

SOURCE Rosetta Genomics
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
2. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
3. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
4. Rosetta Genomics to Webcast Presentation at Maxim Group Growth Conference
5. Rosetta Genomics to Host and Webcast its R&D Day on Friday, October 26, 2007
6. Rosetta Genomics Will Host and Webcast its R&D Day on Friday, October 26, 2007
7. Rosetta Genomics Announces Initiation of In Vivo Studies Following Successful Completion of First Milestone in MicroRNA-based Therapeutic Program for Liver Cancer
8. Rosetta Genomics Selects PCR as Platform for its microRNA-based Diagnostics to be Launched in 2008, Licensed Nanogens MGB Probe Technology
9. GeneNews Chief Scientist Dr. C.C. Liew co-editor of new genomics reference book
10. CODA Genomics Announces Issuance of Optimized Synthetic Gene Production Patent
11. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... PLAINSBORO, N.J. (PRWEB) October 20, 2014 ... that the Sidney Kimmel Cancer Center at Thomas ... program. , Through the Strategic Alliance Partnership ... and OncLive will collaborate to raise awareness of ... cancer treatment, and other projects. Clinicians and other ...
(Date:10/19/2014)... , Oct. 19, 2014 NextCODE Health, which enables ... genome in real time, today announced the launch of its ... Exchange , at the American Society of Human Genetics (ASHG) ... learn more, sign up and apply for free beta access, ... features and benefits can be viewed here . ...
(Date:10/19/2014)... (PRWEB) October 19, 2014 The Asian Orthopedic ... market in Asia with analysis and forecast of revenue. The ... to grow to around $416.5 million by 2018, at a ... through the TOC of the Asian Orthopedic braces and support ... provided. This also provides a glimpse of the segmentation of ...
(Date:10/18/2014)... October 18, 2014 The report ... Trends and Forecasts to 2019", analyzes the global ... order to understand the industry details such as ... across various geographic regions. , Browse 81 Market ... Slides and in-depth TOC on “1,6-Hexanediol Market by ...
Breaking Biology Technology:Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 2The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 3The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 2The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 3The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 41,6-Hexanediol Market Projected to Reach $916.1 Million at a CAGR of 8.3% by 2019 – Report by MarketsandMarkets 21,6-Hexanediol Market Projected to Reach $916.1 Million at a CAGR of 8.3% by 2019 – Report by MarketsandMarkets 31,6-Hexanediol Market Projected to Reach $916.1 Million at a CAGR of 8.3% by 2019 – Report by MarketsandMarkets 41,6-Hexanediol Market Projected to Reach $916.1 Million at a CAGR of 8.3% by 2019 – Report by MarketsandMarkets 5
... BEDFORD, Mass. and MADISON, Wis., July 17 ,Hologic, Inc. ... (Nasdaq:,TWTI) ("Third Wave"), today jointly announced the expiration of ... wholly-owned subsidiary Thunder,Tech Corp. (the "Purchaser") for all outstanding ... period expired, as scheduled, at 12:00,midnight, New York City ...
... Will Focus on Strategies to Promote Legislative Pathway for ... ... (Nasdaq:,INSM), a developer of follow-on biologics and biopharmaceuticals for unmet,medical needs, ... Ways and Means Committee from 2001 to 2007, has been,retained by ...
... Ablative Solution to Treat Deep Wrinkles and Significant Photo Damage,- ... Newest Addition Broadens Affirm(TM) Family to Provide Industry,s Most ... Comprehensive Anti-Aging Solution, ... ), a leading developer and manufacturer of a broad array ...
Cached Biology Technology:Hologic, Inc. Accepts Shares of Third Wave Technologies, Inc. in Tender Offer and Commences Subsequent Offering Period 2Hologic, Inc. Accepts Shares of Third Wave Technologies, Inc. in Tender Offer and Commences Subsequent Offering Period 3Hologic, Inc. Accepts Shares of Third Wave Technologies, Inc. in Tender Offer and Commences Subsequent Offering Period 4Hologic, Inc. Accepts Shares of Third Wave Technologies, Inc. in Tender Offer and Commences Subsequent Offering Period 5Insmed Partners With Bill Thomas, Former House Ways and Means Chairman, as Strategic Advisor 2Insmed Partners With Bill Thomas, Former House Ways and Means Chairman, as Strategic Advisor 3Insmed Partners With Bill Thomas, Former House Ways and Means Chairman, as Strategic Advisor 4Cynosure Introduces Affirm CO2(TM) Workstation for Advanced Ablative Therapy 2Cynosure Introduces Affirm CO2(TM) Workstation for Advanced Ablative Therapy 3Cynosure Introduces Affirm CO2(TM) Workstation for Advanced Ablative Therapy 4
(Date:10/16/2014)... and Washington land managers have a new synthesis of ... moist mixed-conifer (MMC) forests in the two states. ... in Eastern Oregon and Washington: A Synthesis of the ... a general technical report published by the U.S. Forest ... to a request from managers for a synthesis of ...
(Date:10/16/2014)... efficiently, they are anything but sustainable: environmental damage ... is becoming increasingly evident. Despite their disadvantages, however, ... regarded as the sole possibility of achieving higher ... Bernhard Schmid, an ecology professor at the University ... agriculture and forestry. After all, a new study ...
(Date:10/16/2014)... Calif. (October 16, 2014) – Post-menopausal women experienced ... on hormone levels or genital bleeding, after 12 ... an investigational fermented soy germ-based nutritional supplement previously ... to a new peer-reviewed pilot study reported in ... (NAMS) annual scientific meeting. , "These data ...
Breaking Biology News(10 mins):New report synthesizes best available science on management of moist mixed-conifer forests 2Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3S-equol supplements associated with improved measures of reproductive health in postmenopausal women 2
... In new research from Saint Louis University, investigators have ... responsible for the series of cellular events that lead to ... found that the brain toxin DOPAL plays a key role ... In earlier research, Saint Louis University investigators found ...
... about how the flea jumps, think again. In 1967, ... to catapult themselves into the air in an elastic ... debate raged about exactly how fleas harness this explosive ... hypotheses, but neither had access to the high speed ...
... 9, 2011 Qqest and M2SYS Technology, a global ... that allows Qqest to offer TimeForce time and attendance ... identification technology at their PC. M2SYS, RightPunch(TM) ... to seamlessly interface with Qqest,s TimeForce time and ...
Cached Biology News:SLU research implicates natural toxin as triggering Parkinson's disease 244-year-old mystery of how fleas jump resolved 244-year-old mystery of how fleas jump resolved 3Qqest Teams Up With M2SYS to Add Biometric Technology at the Desktop to TimeForce Time and Attendance System 2Qqest Teams Up With M2SYS to Add Biometric Technology at the Desktop to TimeForce Time and Attendance System 3
... 140kDa GenBank Accession ... amino acids 926-941 (DKKVKPPFIPTIRGRE) of human PRK2. ... Quality Assurance Routinely evaluated by ... Stability 1 year at ...
Replacement Parts for Electrophoresis Apparatus...
Rabbit anti-phospho-EGFr (Tyr992) - Concentrate...
EMBP (FL-222)...
Biology Products: